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Si.inmary The T-cell receptor (TCR) repertoire expression of tumour-infiltrating lymphocytes (TILs) from 19
nasopharyngeal carcinoma (NPC) biopsies was compared with those of lymphocytes from 18 control
nasopharyngeal biopsies. mRNA was extracted from these lymphocytes and the cDNA transcribed. A panel of
18 VaE- and 21 VA-specific primers was used to detect the TCR gene use from cDNA. The use of VcE and VP
genes was restricted in TILs compared with lymphocytes from biopsies. The frequencies of Ve2, VO3, Vx9,
VaO0, VaEl, Va13, Va14, Va15, V011, VP14, VP15 and VP20 were decreased and the frequencies of ValO
[P, = 0.04; relative risk (RR) = 0.05], Val1 (P, = 0.02; RR = 0.07), Va13 (P, = 0.002; RR = 0), VaEl4
(P= 0.04; RR = 0.05), VP14 (P =O0.001; RR = 0.03) and V)2 (P =O0.001; RR = 0.03) remained signifi-
cantly reduced after correction for the number of families typed. The frequency of Val7 was higher in NPC
biopsies than in NPC PBLs (P = 0.05), and the frequency of VP15 was lower in NPC biopsies than in NPC
PBLs (P= 0.02). The frequencies of Val7 and Va18 in HLA-B46' patients were significantly lower
(P = 0.009; P = 0.044) than in B46 + controls. The results suggest that the restriction of TCR gene use in NPC
patients may be important in NPC pathogenesis.
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Most mature T lymphocytes specifically recognise antigens
presented on MHC molecules through the T-cell receptor
(TCR). Analysis of the tumour-infiltrating lymphocytes
(TILs) may help to clarify their fole in tumour cell destruc-
tion and to achieve a better understanding of the cellular and
molecular basis of lymphocyte-tumour interaction.
Nasopharyngeal carcinoma (NPC) is an epithelial tumour
characterised by a marked lymphocytic infiltration (Shan-
mugaratnam et al., 1979>. HLA-B46 and -B58 haplotypes are
associated with NPC (Chan et al., 1983). These same alleles
are also associated with autoimmune diseases in the Chinese
(Chan et al., 1978, 1981, 1993, 1994; Lee et al., 1983),
suggesting that these HLA alleles may be associated with
abnormal immune functions. Since HLA molecules present
foreign and self peptides to T cells via TCR, the restricted
HLA alleles may result in a restriction of antigen/MHC
combinations as well as a restriction of TCR expression. The
association of HLA and TCR in autoimmune diseases has
been well documented (Oksenberg et al., 1990; Wucherpfen-
nig et al., 1990, 1992; Ben-Nun et al., 1991; Davies et al.,
1991, 1992; Sioud et al., 1991, 1992; Sottini et al., 1991;
Giegerich et al., 1992; Martin et al., 1992; Sumida et al.,
1992; Utz et al., 1993). Recent studies have also demon-
strated the association between TCR and some malignancies,
such as melanoma (Nitta et al., 1990, 1991a,b; Bennett et al.,
1992; Weidmann et al., 1993), glioma, medulloblastoma
(Nitta et al., 1991b) and pulmonary and renal carcinomas
(Bennett et al., 1992), suggesting that these malignant neop-
lasms may have stimulated a specific T-lymphocyte response
through antigen recognition by the TCR. NPC is also
associated with the Epstein-Barr virus (EBV), with high
antibody titres to various EBV antigens and low T-
cytotoxicity levels (Chan et al., 1979; Moss et al., 1983).
These abnormal immune responses to EBV may result from
inappropriate T-cell responses to HLA/EBV peptide com-
binations. TCR gene polymorphism in NPC has been shown
(Chen and Chan, 1994), and we are further investigating
whether there are particular TCR uses or lack of in TILs in
NPCs, especially in those with HLA-B46 and -B58.
The present study summarises an analysis of TCR variable
gene family expression in peripheral blood lymphocytes
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(PBLs) and TILs in Singaporean Chinese NPC patients and
controls using the polymerase chain reaction (PCR) techni-
que. The results showed that there were differences in TCR
gene expression between NPC patients and controls: NPC
patients had lower frequency of expression of some TCR
gene families in PBLs and TILs compared with controls.
Mateiads and methods
Biopsies
Surgical biopsies were obtained from 37 untreated patients
suspected of having NPC seen for the first time at a major
ENT out-patient clinic. From subsequent histopathology
results, there were 19 NPC patients and the 18 biopsy-
negative patients served as controls. Patients and controls
were Chinese from Singapore. The biopsies were collected in
sterile medium and processed within 4 h.
Preparation of TILs
Fresh biopsies were teased with two pairs of forceps in a 3.5
cm Petri dish containing 1 ml of RPMI-1640. The released
cell suspension was transferred to a 15 ml tube and washed
once with 10 ml of RPMI-1640. The cells were resuspended
and cultured (37C with 5% carbon-dioxide) in RPMI-1640
with 10% heat-inactivated pooled human serum (from blood
donors) and 15 u ml-' interleuk-in 2 (IL-2) (Boerhinger Man-
nheim). TILs were cultured for 1-2 weeks and the medium
(with IL-2) replaced every other day. Cells were harvested by
washing three times in 15 ml of phosphate-buffered saline
(PBS)-glucose and the cell pellet frozen immediately at
- 70C. The frozen cells were thawed for RNA extraction in
batches.
Peripheral bloodsamples andpreparation ofPBLs
Peripheral blood samples were also obtained from the
patients and controls at the time of the biopsy. Heparinised
blood was mixed with an equal volume of PBS-glucose and
centrifuged over a Ficoll-Hypaque density gradient for
20 min at 2000 r.p.m. Cells from the interface were collected
and washed twice with PBS-glucose. The peripheral blood
lymphocytes were cultured and harvested the same way asTCRpni p inl KC
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TILs. HLA typing was also performed on the separated
peripheral blood before culture.
Preparation ofRNA
mRNA from biopsy lymphocytes and PBLs was prepared by
using the QuickPrep Micro mRNA Purification Kit (Phar--
macia). Briefly, l06-i0' cells were extracted in a buffered
solution containing a high concentration of guanidinium
thiocyanate (GTC) and then diluted 3-fold with elution buf-
fer. The supernatant clarified by centrifugation was transfer-
red to a microcentrifuge tube containing oligo(dT)-cellulose.
After 3 min, during which time the poly(A) RNA bound to
the oligo(dT)-cellulose, the tube was centrifuged at 12 000
r.p.m. for lOs. The pelleted oligo(dT)-cellulose was then
washed five times with high-salt buffer and twice with low-
salt buffer. The oligo(dT)-cellulose slurry was transferred to
a MicroSpin column. Polyadenylated RNA was eluted with
elution buffer, prewarmed at 65°C and precipitated in the
presence of one-tenth the volume of potassium acetate and
2.5 volumes of 100% ethanol for a minimum of 2 h at
-20°C.
cDNA synthesis
An aliquot of 1-2iLg of mRNA was used for the synthesis of
single-strand cDNA in a final volume of 40 ,l, with 50 mM
Tris-HCl, 75 mM potassium chloride, 3 mM magnesium
chloride, 10 mM dithiothreitol (DTT), 0.5 mM dNTP (Pro-
mega), 80 units of RNAsin (Promega), 0.2iLg of oligo(dT)
(New England Biolabs) and 400 units of SuperScript reverse
transcriptase (Gibco BRL). The reaction mixture was
incubated for 1 h at 37TC and heated at 95°C for 5 min.
PCR
A 1 gil volume of single-stranded cDNA was amplified using
either a Va-specific and C4 primers or a VP-specific and Cp
primers at a final concentration of 0.5 .LM in each reaction.
Sequences of individual primers are listed in Table I (Nitta et
al., 1991a; Sottini et al., 1991). The size ofamplified products
ranged from 250 to 450 bp. Oligonucleotides were syn-
thesised (Biosynthesis, USA) and the amplification was per-
formed with 1 unit of Taq polymerase (Perkin Elmer) on a
DNA thermal cycler (Perkin Elmer). The PCR cycle profile
was denaturation at 95'C for 1 min, annealing of primers at
55°C (a-chain) or 50°C (a-chain) for 1 min and extension of
reaction at 72°C for 1 min for 35 cycles. PCR products were
separated on 1.4% agarose gels. Expression of Va or VP
genes was considered positive when a correct size band
(250-450 bp) was visualised after ethidium bromide staining
and when the amplified products were positively hybridised
with Ca- or Cp-specific oligonucleotide probe on Southern
blots.
Southern blot analysis
Ten microlitres of amplified products was electrophoresed in
a 1.4% agarose gel for 40min and transferred on nylon
membrane (Amersham Aylesbury, UK) as described by
Southern (1975). Filters were prehybridised at 42°C in
6 x SSPE/5 x Denhardt's/0.1% bovine serum albumin
(BSA)/0.1% sodium sarcosine /0.2% sodium dodecyl sul-
phate (SDS) for 30 min and hybridised for 2 h at 42°C with
digoxigenin-labelled deoxyuridine triphosphate (Dig-dUTP,
Boehringer Mannheim) Co or CP oligonucleotide probes. The
filters were washed with 2 x SSPE/0.1% SDS twice at room
temperature for 5 min, followed by washing with 2 x SSPE/
0.1% SDS at 60C (Va) or 50C (VP) for lOmin twice and
with 2 x SSPE at room temperature for 5 min twice. The
filters were blocked with skimmed milk for 30 min and then
incubated with alkaline phosphatase (AP)-conjugated anti-
digoxigenin antibody for 30 min in the presence of 0.1 M Tris
and 0.15 M sodium chloride. The colour was developed in the
presence of 5-bromo-4-chloro-3-indolyl phosphate (X-
phosphate) and nitroblue tetrazolium (NBT).
Statistic analysis
The frequencies of VcE or VP expression in patients and
controls were analysed using the X2 and Fishers' exact test.
To minimise the possibility of obtaining significant
differences by pure chance, the P-value was multiplied by the
number of Va (18) or VP (21) families tested to give the
corrected P (PJ value. Relative risks (RR) were the cross-
products of the cells in 2 x 2 tables and the 95% confidence
limits (CL) calculated.
Results
Optimisation ofprimers
To analyse TCR Vax and VP repertoire expression in this
study, PCR amplification using 18 Vm- and 21 VP-specific
primers was performed. To test and optimise the primers,
mRNA from PBLs of normal individuals was isolated and
Table I Sequence of the primers used in the present study
Priners 5'-3' sequence
Val
Vc2
Vm3
VcE4
Va5
Vcx6
Va7
Vm8
Vd0
Vaxl3
VE14
Vaxl5
Val6
Vx17
Vx18
CO3'
CO5'
Primers 5'-3' sequence
TTGCCCTGAGAGATGCCAGAG
GTGTTCCCAGAGGGAGCCATTGCC
GGTGAACAGTCAACAGGGAGA
ACAAGCATTACTGTACTCCTA
GGCCCTGAACATTCAGGA
GTCACT-CTAGCC1TGCTGA
AGGAGCCATTGTCCAGATAAA
GGAGAGAATGTGGAGCAGCATC
ATCTCAGTGCTTGTGATAATA
ACCCAGCTGGTGGAGCAGAGCCCT
AGAAAGCAAGGACCAAGTGTT
CAGAAGGTAACTCAAGCGCAGAC1T
GCTTATGAGAACACTGCGT
GCAGCTTCCCTTCCAGCAAT
AGAACCTGACTGCCCAGGAA
CATCTCCATGGACTCATATGA
GACTATACTAACAGCATGT
TGTCAGGCAATGACAAGG
AATAGGTCGAGACACTTGTCACTGGA
CAGAACCCTGACCCTGCCGTGTAC
Vp1
VP2
VP3
VP4
VP5.1
VP5.2
VP6
VP7
VP8
VP9
Vv10
VP12
VP13
VP14
VP15
VP16
VP17
VP18
Vl19
VP20
CP3'
cl5'
GCACAACAGTTCCCTGACITTGCAC
TCATCAACCATGCAAGCCTGACCT
GTCTCTAGAGAGAAGAAGGAGCGC
ACATATGAGAGTGGATTTGTCATT
ATACTTCAGTGAGACACAGAGAAAC
TTCCCTAACTATAGCTCTGAGCTG
AGGCCTGAGGGATCCGTCTC
CCTGAATGCCCCAACAGCTCTC
ATTTAC1TTTAACAACAACGTTCCG
CCTAAATCTCCAGACAAAGCTCAC
CTCCAAAAACTCATCCTGTACCTT
TCAACAGTCITCCAGAATAAGGACG
AAAGGAGAAGTCTCAGAT
CAAGGAGAAGTCCCCAAT
GTCTCTCGAAAAGAGAAGAGGAAT
AGTGTCTCTCGACAGGCACAGGCT
AAAGAGTCTAAACAGGATGAGTCC
CAGATAGTAAATGAC1-TCAG
GATGAGTCAGGAATGCCAAAGGAA
CAATGCCCCAAGAACGCACCCTGC
AGCTCTGAGGTGCCCCAGAATCTC
GTGCACCTCCTTCCCATT
GTGTTTGAGCCATCAGAAtranscribed into cDNA. All Vcx gene families and VP gene
families except VP16 were successfully amplified as visualised
with ethdium bromide-stained correct-sized products, and
a
460 bp _-.
222 bp -
b
C
460 bp -
222 bp -
d
Fuwe I Examples ofTCR Vz gene usage in control biopsies (a,
gel; b, Southern blot) and in NPC biopsies (c, gel; d, Southern
blot).
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primer specificities were further confirmed by hybridisation
of a Dig-dUTP-labelled Ca or Ci oligonucleotide probe
(data not shown).
TCR Va gene expression in TILs and control biopsies
TILs and lymphocytes from control biopsies were isolated
and cultured for 1-2 weeks and mRNA was extracted to
prepare cDNA transcript as a template for the PCR. Overall,
of the 18 different Va gene families, the average number of
Va genes used was 15.3 in control biopsies (n = 18) and 9.6
in NPC TILs (n = 17). TILs also showed less Va repertoire
expression than lymphocytes from control biopsies. The 18
families ofVa genes were not equally represented and not all
the VaE genes were detectable in all subjects, indicating that
some TCR genes were not being expressed (Figure 1). NPC
TILs showed considerable individual variation in TCR exp-
ression. Most of the TIL samples did not express the com-
plete range of Va families and lacked as many as 13 gene
families. When the frequency of specific TCR families was
analysed, there were lower frequencies of Va2, VW3, Vx9,
ValO, VEll, Vaz13, Vcz14 and Vl.5 genes in TILs compared
with those of control biopsies. Of these, Vz10, Vall, Vx13
and VE14 showed significantly lower frequency of expression
even after correction for the number of families typed (Table
II). None ofthe TCR families was expressed more frequently
in TTLs than in control biopsies.
TCR VP gene expression in TILs and control biopsies
Twenty-one VA gene repertoires were analysed. The average
number of VP genes used was 18.6 (n = 18) in control biop-
Table H Summary of TCR Vz and VA gene expression in NPC and control biopsies
TCR NPC+ biopsies Frequency NPC- biopsies Frequency P PI RR 95% CL
Vz +(n= 17) +(n= 18)
Val 14 0.824 18 1.000
Vz2 10 0.589 17 0.944 0.015 NS
Va3 10 0.589 18 1.000 0.003 NS
Vm4 11 0.647 13 0.722
Vm5 4 0.235 8 0.444
Vm6 13 0.765 18 1.000
Va7 13 0.765 18 1.000
Vm8 7 0.412 9 0.500
Va9 8 0.471 16 0.889 0.009 NS
Vz10 8 0.471 17 0.944 0.002 0.04 0.05 0.01-0.49
Val 1 6 0.353 16 0.889 0.001 0.02 0.07 0.01-0.40
Val2 14 0.824 18 1.000
Val3 7 0.412 18 1.000 1.1 x 10-4 0.002 0
Val4 8 0.471 17 0.944 0.002 0.04 0.05 0.01-0.49
VM15 10 0.588 17 0.944 0.015 NS
Vm16 7 0.412 13 0.722
Val7 8 0.471 13 0.722
Val8 5 0.294 12 0.667
VP +(n= 19) +(n= 18)
V01 19 1.000 18 1.000
VP2 19 1.000 18 1.000
V03 16 0.842 18 1.000
V04 18 0.947 18 1.000
V05.1 17 0.895 17 0.944
V05.2 17 0.895 18 1.000
V06 19 1./000 18 1.000
V07 19 1.000 18 1.000
VP8 13 0.684 17 0.944
V09 16 0.842 18 1.000
V010 13 0.684 17 0.944
V011 8 0.421 16 0.889 0.003 NS
V012 16 0.842 17 0.944
V013 15 0.789 18 1.000
V014 4 0.211 16 0.889 3.7 x 10-5 0.001 0.03 0.01-0.2
V015 13 0.684 18 1.000 0.01 NS
V016 0 0.000 0 0.000
V017 14 0.737 18 1.000
V018 13 0.684 17 0.944
V019 15 0.789 18 1.000
V020 11 0.579 18 1.000 0.002 0.04 0
.L
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sies and 15.5 (n = 19) in TILs. The usage of TCR VP genes
was more heterogeneous and most of the samples expressed
most of the VP genes (Figure 2). However, VP11, V014, V015
and Vl20 in TILs showed lower frequency of use than
a
350 bp-_
222 bp-
D
C
350 bp _.
222 bp
-
'i
Fugwe 2 Examples of TCR VA gene usage in control biopsies (a,
gel; b, Southern blot) and in NPC biopsies (c, gel; d, Southern
blot).
controls (Table II); V014 and VP20 remained significant after
correction.
TCR gene expression in NPC PBLs and control PBLs
To investigate the expression of TCR genes in NPC PBLs,
mRNA was isolated from 15 NPC PBLs and eight control
PBLs, cDNA transcribed and PCR performed. The average
number of TCR Va genes used was 10.1 in NPC PBLs and
15.3 in control PBLs. The frequency of expression of Va2,
Va8, Vall, Va13, Va14, Val6 and Val7 in PBLs was lower
than in control PBLs, and none remained significant after
correction (Table III). The average number ofVP genes used
was 17.3 in NPC PBLs (n= 15) and 19.3 in control PBLs
(n = 8). The frequency of VP14 was again significantly lower
in NPC PBLs than that in control PBLs and remained so
after correction (Table HII; P, = 0.05; RR = 0).
Comparison of TCR gene expression in TILs and PBLs of
NPCpatients
TCR Va genes of NPC TILs and PBLs were compared and
the results showed similar average numbers of Vcx use. Most
of the Va genes that were expressed in PBLs were also
expressed in TILs, and most of those which were not exp-
ressed in PBLs were not expresed in TILs as well. The
frequency of expression of Vx3, Va9, Vall and Val5 was
lower and the frequency of Va4, Va16 and Val7 was higher
in TILs than in PBLs. However, the difference in frequency
of expression was only significant for Val7 (P = 0.05). The
average VP gene expression in TILs and in PBLs in NPC
patients was identical. The frequency of expression of V010,
Table m Summary of TCR Va and VP gene expression in PBLs and control
TCR NPC PBLs Frequency Control PBLs Frequency P Pc RR 95% CL
Va +(n = 14) +(n = 8)
Val 11 0.786 8 1.000
Va2 8 0.571 8 1.000
Vm3 12 0.857 8 1.000
Va4 6 0.429 3 0.375
Va5 4 0.286 1 0.125
Va6 12 0.857 8 1.000
Va7 9 0.643 8 1.000
Va8 6 0.429 8 1.000 0.009 NS
Va9 10 0.714 8 1.000
ValO 9 0.643 8 1.000
Va 1 8 0.571 8 1.000
Val2 10 0.714 8 1.000
Val3 8 0.571 8 1.000
Val4 7 0.500 8 1.000 0.02 NS
Val5 12 0.857 8 1.000
Val6 4 0.286 6 0.750
Val7 2 0.143 6 0.750 0.008 NS
Val8 4 0.286 2 0.250
VP +(n = 15) +(n=8)
Vp1 15 1.000 8 1.000
VP2 15 1.000 8 1.000
VP3 15 1.000 8 1.000
VP4 15 1.000 8 1.000
VP5.1 15 1.000 8 1.000
VP5.2 14 0.933 8 1.000
VP6 15 1.000 8 1.000
VP7 15 1.000 8 1.000
VP8 11 0.733 8 1.000
Vp9 14 0.933 8 1.000
Vp10 12 0.800 5 0.625
Vpl I 10 0.667 5 0.625
V012 13 0.867 8 1.000
VP13 13 0.867 8 1.000
VP14 5 0.333 8 1.000 0.003 0.05 0
VP15 15 1.000 8 1.000
VP16 0 0.000 0 0.000
VP17 13 0.867 8 1.000
VP18 11 0.733 8 1.000
Vpl9 13 0.867 8 1.000
VP2 10 0.667 8 1.000
uTCRgum
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Vpll and VP15 was lower in TILs than in PBLs. The
difference in VP15 reached statistical signifie (P = 0.02).
TCR and HLA
NPC in the Chine isassociated with HLA-B46 and HLA-
B58 (Chan et al., 1983). Vdl7 was observed in 2/8 (25%)
B46+ NPC paients compared with 6/6 (100%) B46+ cont-
rols (P = 0.009; RR = 0). Among the HLA-B46- subjects,
the frequency of Val7 showed nosigificant difference
between NPC patients and controls. Similarly, Val8 was
observed in 3/8 (37.5%) HLA-B46+ NPC patients compared
with 5/5 (1I00%) B46+ controls (P = 0.044; RR = 0). The
frequency of Val8 also showed no difference betwen B46-
patients and controls. However, among B46- controls the
frequency of Val8 was lower (1/5, 20%) than in B46+
controls
(6/6, 100%; P = 0.015).
T cells that recognse and respond to a specific antigenic
peptide by activation and prolferation are considered to be
clonally restrcted and to express a imited number of TCR
genes (Innide and Whiteside, 1993). The complexity of
TCR use in the anti-tumourresonse may result from the
involvement of multiple m- and A-chain regions in response to
a single antigenic determinant or may reflect mutiple
antigenic determinantsexp on tumour cells.
Our previous study on rition f ent length
polymorphism (RFLP) of TCR genes indicated that there is
polymorphism of TCR genes in NPC patients (Chen and
Clha, 1994). In the present study, TCR gene expression in
TILs and PBLs from NPC patients andin lymphocytes from
control biopsies and control PBLs were investigated. TCR
Va genes in NPC TILs showedlimited heterogeneity com-
pared with lymphocytes from control biopsies. The frequen-
cies of Va2, VO3, Va9, ValO, Vall, Val3, Val4 and Val5
were lower in TILs and, in particular, the frequencies of
ValO, Vall, Val3 and Val4 weresignifcntly lower than in
controls even after correction for the number of Va gene
families studied. Since we were loking for the expresson of
many Va and VP families in the same cDNA sample,
differences in frequencies between patients and controls may
occur by pure chance. We have attempted to correct for this
by multiplying the P-value by the number of Va or VP
families typed, a common practice used in HLA and disease
statistics. The frequency of VP gene expression in TLUs was
more heterogeneous than that of Va genes. The frequencies
of VP1, VP14, VP15 and VP20 were reduced compared with
controls, but only VP14 and V020 showed sgnificntly
reduced frequency after correction. In our previous study of
genomic TCR pattens, NPC patients had a VPI1/IlBnHI
allelic pattern significantly different from controls (Chen and
Chan, 1994). VP 1I was again affected in the present study,
showing a lower frequency of rearrangement in the TILs, and
the two findings may be related.
TILs showed individual variation in TCR expresson. The
differences in TCR gene expression detected among the indi-
viduals may be related to TCR V-gene polymorphisms that
impose the utilisation of different V-gene segments for the
recognition of the same antigen. Retriction of TCR use may
also be influenced by a person's HLA type. In this regard, it
is interesting to note that NPC patients with HLA-B46 had
lower frequencies of Va17 and Va18 than to B46+ controls,
suggesting that the combination of HLA restriction and lack
of TCR gene use may be important in the pathogenesis of
NPC. Lymphocytes from biopsies of all normal controls with
HLA-B46 expressed Val7 and Va18, but only 25% and
37.5% of TILs, respectively, expressed these markers.
TIs in NPC are mainly mature T lymphocytes with
different ratios of CD4+ /CD8 + cells. It is important to
investigate the TCR usein T-cell subgroups. We have
preliminarily anlysed TCR use between total and CD4+ T
cellsin thesame patients and controls. While there was no
difference in TCR use between total T cells and CD4 + T
cells in the two controls, both NPC patients showed even
morer cted TCR family usein the CD4+ TceIls com-
Oared with total T cells. The number of patients and controls
stuied was too small to make any firm conclusion but
suggets that TCR use in NPC may be even more restritd
in the T-helper cell subpopulation.
The present results showed that VaO0, ValI, Va13, Va14,
VP14 andV020 were underexpressed in NPC TILs, sugges-
ting that these genes may have been deleed. Nasopharyngeal
biopsies are usuallysmal, and it may be pure chance that T
cellswith certain TCR rearrangements are not represented.
However, arguingagainst this possibility was the finding
that, in general, those TCR rearrangements not present in
TILs were also notreprntedin the peripheral blood of
most patients. Not all patients or controls have matching
biopsies and peripheral blood samples. In those that have
matching pairs, the concordance of Vz and VP bands
between biopsy and peripheral blood was usually over 90%
(e.g.Va10, 91%;Va13, 91%; VP14, 92%). TILs and PBLs in
our study had been cultured in vitro for 1-2 weeks, and there
was no difference in culture time between NPC patients and
controls. The cultures were all growing well at the time of
harvest It is possible that only certain TCR famili were
expansion. However, in our study, no preferential
use of certain TCR genes was observed, and there is so far
no evidence to support this. TCR Va gene expression with or
without culture showed little difference other studies
(Davies et at., 1991), and culture with IL-2 reduced rather
than ehanced the degree of rstiction. It is possible that T
cells with cerain TCRs fail to growin thepresece ofIL-2.
However, T cells with these TCRs grew well in control
cultures. On the otherhand, immunosuppressed T cells may
behave differently, and it is possible thatsu ed T cells
with certain TCRs may not grow in thepresence of IL-2, and
we are exploring this possibility. Whether the deletion of
these TCR genes leads to failure of T-cell recognition of
tumour peptide/HLA complexes resulting in the escape of
NPC tumours from immune surveillance, or whether NPC
results in the deletion of specific TCR genes also need to be
investigated We found no specific TCR gene use in NPC,
but rather a specific deletion of certain TCR genes, and this
finding together with HLA restriction may be important in
the pathogenesis of NPC.
TI, tumour-infiltrating lymphocyte; PBL, peripal blood lym-
phocyte; NPC, nasopharynga carinoma; HLA, huiman keucocyte
antigen; TCR, T-celrmeptor, RPMI, Roswell Park Memorial Insti-
tute; IL-2, interkukin 2; PBS, phosphate-buffered saline.
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